Kelly R A, O'Hara D S, Mitch W E, Steinman T I, Goldszer R C, Solomon H S, Smith T W
Kidney Int. 1986 Nov;30(5):723-9. doi: 10.1038/ki.1986.247.
Endogenous digitalis-like factors have been implicated in the adaptations that accompany renal insufficiency and in the pathogenesis of hypertension. We recently described several fractions of normal human plasma that inhibit NaK-ATPase and exhibit apparent digoxin-like immunoreactivity. To determine if hypertension and/or renal insufficiency affect plasma levels of these factors, we examined four patient groups: normotensive controls; hypertensive subjects with normal renal function; hypertensives with moderate renal insufficiency; and chronic dialysis patients. Plasma levels of digoxin-like immunoreactivity and NaK-ATPase inhibitory activity were significantly increased in hypertensive patients with mild renal failure (7.6 +/- 1.1 ouabain equivalents, mean +/- SEM, N = 21 vs 4.1 +/- 1.1 in normotensive controls, N = 20, P less than 0.05). NaK-ATPase inhibitory activity tended to be higher in patients with primary hypertension and normal renal function (5.5 +/- 0.7 ouabain equivalents, P less than 0.07); in dialysis patients, it was not different from controls. There was no correlation between NaK-ATPase inhibitory activity and blood pressure in any group. There was a significant rise in plasma NaK-ATPase inhibitory activity during dialysis (+ 1.8 +/- 0.7 ouabain equivalents, N = 22, P less than 0.03). As we have found that NaK-ATPase inhibitory activity in the plasma of normal humans can be separated into three distinct fractions, EI1, EI2, and EI3, we analyzed the plasma of 10 dialysis patients further. The increase in NaK-ATPase inhibitory activity could be attributed to fractions EI1 and EI3. These results suggest that plasma NaK-ATPase inhibitors increase with chronic renal insufficiency, but not hypertension alone. Although hemodialysis may acutely raise plasma levels, long-term dialysis returns them to the normal range.
内源性类洋地黄因子与肾功能不全时的适应性变化以及高血压的发病机制有关。我们最近描述了正常人血浆中的几个组分,它们能抑制钠钾 - ATP酶并表现出明显的地高辛样免疫反应性。为了确定高血压和/或肾功能不全是否会影响这些因子的血浆水平,我们检查了四组患者:血压正常的对照组;肾功能正常的高血压患者;中度肾功能不全的高血压患者;以及慢性透析患者。轻度肾功能衰竭的高血压患者血浆中的地高辛样免疫反应性和钠钾 - ATP酶抑制活性显著升高(7.6±1.1哇巴因当量,平均值±标准误,N = 21,而血压正常的对照组为4.1±1.1,N = 20,P<0.05)。原发性高血压且肾功能正常的患者钠钾 - ATP酶抑制活性往往较高(5.5±0.7哇巴因当量,P<0.07);透析患者的该活性与对照组无差异。任何一组中钠钾 - ATP酶抑制活性与血压之间均无相关性。透析过程中血浆钠钾 - ATP酶抑制活性显著升高(+1.8±0.7哇巴因当量,N = 22,P<0.03)。由于我们发现正常人血浆中的钠钾 - ATP酶抑制活性可分为三个不同组分,EI1、EI2和EI3,我们进一步分析了10名透析患者的血浆。钠钾 - ATP酶抑制活性的升高可归因于EI1和EI3组分。这些结果表明,血浆钠钾 - ATP酶抑制剂随慢性肾功能不全而增加,但单独高血压时不会增加。虽然血液透析可能会急性升高血浆水平,但长期透析会使其恢复到正常范围。